Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic
|ClinicalTrials.gov Identifier: NCT00490373|
Recruitment Status : Completed
First Posted : June 22, 2007
Last Update Posted : June 22, 2007
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Drug: pemetrexed||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||52 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 Trial of ALIMTA in Pretreated Patients With Unresectable or Metastatic Cancer of the Pancreas|
|Study Start Date :||October 2003|
|Actual Study Completion Date :||April 2005|
- To evaluate the efficacy.
- To assess tumor response.
- To assess time to event efficacy variables including time to progressive disease and overall survival.
- To characterize the quantitative and qualitative toxicities of pemetrexed in this population of pancreatic cancer patients.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00490373
|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.|
|Study Director:||Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)||Eli Lilly and Company|